Immune suppression in renal cell carcinoma

被引：36

作者：

Frankenberger, Bernhard

Noessner, Elfriede

Schendel, Dolores J.

机构：

[1] GSF Munich, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany

[2] GSF Munich, Natl Res Ctr Environm & Hlth, Clin Cooperat Grp, D-81377 Munich, Germany

来源：

SEMINARS IN CANCER BIOLOGY | 2007年 / 17卷 / 04期

关键词：

renal cell carcinoma; Immune suppression; tumor escape; cytokine therapies; immune therapies;

D O I：

10.1016/j.semcancer.2007.06.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clear evidence that tumor-infiltrating lymphocytes with anti-tumor activity exist in situ raises the question why renal cell carcinomas (RCCs) progress in vivo. A complex array of factors and pathways has been identified that impinges on innate and adaptive effector cells thereby inhibiting their activity against RCCs. The current picture of suppressive mechanisms that contribute to the failure of the immune system to control RCCs is reviewed here. Understanding these complex host-tumor interactions has broad implications for successful application of cytokine therapy and other forms of immunotherapy for RCC. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：330 / 343

页数：14

共 136 条

[111] Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB1*0401+ patients with renal cell carcinoma or melanoma [J].